The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Other Relationship - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Roche; Takeda
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
 
Naiyer A. Rizvi
Leadership - ARMO BioSciences
Stock and Other Ownership Interests - ARMO BioSciences; Gritstone Bio
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Regeneron
 
Byoung Chul Cho
Stock and Other Ownership Interests - Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Niels Reinmuth
No Relationships to Disclose
 
Ki Hyeong Lee
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD
 
Alexander Luft
No Relationships to Disclose
 
Myung-Ju Ahn
No Relationships to Disclose
 
Michel van den Heuvel
No Relationships to Disclose
 
Manuel Cobo Dols
No Relationships to Disclose
 
David Vicente
No Relationships to Disclose
 
Alexey Smolin
Consulting or Advisory Role - AstraZeneca; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
 
Vladimir Moiseyenko
No Relationships to Disclose
 
Scott Joseph Antonia
Stock and Other Ownership Interests - Cellular Biomedicine Group
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cellular Biomedicine Group; Memgen; Merck; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; FLX Bio; Memgen; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; FLX Bio; Merck; Novartis
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; CareNet; Chugai Pharma; Clinical Trial Co; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Merck Sharp & Dohme; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Reno Medical; SymBio Pharmaceuticals; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Speakers' Bureau - Astellas Pharma; Ono Pharmaceutical; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); Gritstone Bio (Inst); ICON Clinical Research (Inst); inVentiv Health (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Linical (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Quintiles Inc. (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Sarah B. Goldberg
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Spectrum Pharmaceuticals
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Immunogen (Inst); Kadmon (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Edward S. Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Research Funding - Boehringer Ingelheim; Genentech/Roche; Ignyta; Merck
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Merck; Pfizer; Takeda
 
Jill Walker
Employment - AstraZeneca
 
Rajiv Raja
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
 
Feng Liu
Employment - AstraZeneca
 
Urban J. Scheuring
Employment - AstraZeneca
 
Solange Peters
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; Merck Serono; MSD; Novartis; Pfizer; Regeneron; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche